Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.

PharmacoEconomics
Greg L Plosker

Abstract

This article briefly summarizes the burden of bipolar disorder and the clinical profile of quetiapine (Seroquel®) in the management of bipolar disorder, followed by a detailed review of pharmacoeconomic analyses. Quetiapine is an atypical antipsychotic that is available in numerous countries as immediate-release and extended-release tablets for the treatment of major psychiatric disorders, including bipolar disorder. Randomized, double-blind, placebo-controlled trials with quetiapine have demonstrated its efficacy in bipolar I and II disorders, and the drug has been generally well tolerated in clinical trials. Three cost-effectiveness analyses of maintenance therapy in bipolar I disorder, which used similar Markov models and incorporated data from key clinical trials and a number of other sources, showed that quetiapine, as adjunctive therapy with mood stabilizers (lithium or divalproex), was a cost-effective treatment option from the healthcare payer perspective in the UK and the US. Quetiapine either dominated comparators (typically mood stabilizers alone) or was associated with incremental cost-effectiveness ratios that were usually well below widely accepted thresholds of cost effectiveness. One of the studies evaluated ext...Continue Reading

References

Jul 24, 1996·JAMA : the Journal of the American Medical Association·M M WeissmanE K Yeh
Oct 3, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·G E Simon, J Unützer
Jan 6, 2000·The British Journal of Psychiatry : the Journal of Mental Science·D PerlickR Rosenheck
Jul 24, 2001·PharmacoEconomics·C E BegleyL Bryant-Comstock
Mar 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Roben Das Gupta, Julian F Guest
Jan 10, 2003·Bipolar Disorders·Lynda Bryant-ComstockGiovanna Devercelli
Jul 2, 2003·The American Journal of Psychiatry·Pamela B PeeleDavid J Kupfer
Sep 6, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Siegfried Kasper
Mar 5, 2004·Der Nervenarzt·C Runge, H Grunze
Sep 16, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Hans-Georg EichlerBengt Jönsson
Oct 2, 2004·Acta Psychiatrica Scandinavica·L Hakkaart-van RoijenF F H Rutten
May 26, 2005·JAMA : the Journal of the American Medical Association·David J Kupfer
Jul 5, 2005·The American Journal of Psychiatry·Joseph R CalabreseJamie Mullen
Sep 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Roger S McIntyreJamie Mullen
Oct 15, 2005·BMJ : British Medical Journal·Deborah M CaldwellJ P T Higgins
Feb 25, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·J Sloan Manning
Mar 29, 2006·The Journal of Clinical Psychiatry·Frank D GianfrancescoRuey-hua Wang
Jun 28, 2006·CNS Drugs·Rachael L FleurenceDennis A Revicki
Nov 18, 2006·Journal of Clinical Psychopharmacology·Michael E ThaseUNKNOWN BOLDER II Study Group
May 10, 2007·Drugs·Gillian M Keating, Dean M Robinson
May 15, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Nancy C BrahmRyan M Carnahan
Oct 11, 2007·The Annals of Pharmacotherapy·Mariam HassanLesley-Ann Miller
Jan 18, 2008·The New England Journal of Medicine·Erick H TurnerRobert Rosenthal
Oct 25, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Carlos FigueroaHelen Winter
Jan 27, 2009·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Liberty FajutraoAnne Heyes
Feb 10, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Mariam Hassan, Maureen J Lage
Sep 23, 2009·Journal of Medical Economics·Tatia Chay WoodwardArthur Lazarus
Feb 4, 2010·The Journal of Clinical Psychiatry·Susan L McElroyUNKNOWN EMBOLDEN II (Trial D1447C00134) Investigators
Feb 4, 2010·The Journal of Clinical Psychiatry·Allan H YoungUNKNOWN EMBOLDEN I (Trial 001) Investigators

❮ Previous
Next ❯

Citations

May 20, 2015·Journal of Medical Economics·Krithika RajagopalanAntony Loebel
Apr 29, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Ather Muneer
Dec 12, 2013·Expert Review of Clinical Pharmacology·Enrico CocchiAlessandro Serretti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here